NCT06480240 - A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

OBI-992

OBI-992 is an antibody-drug conjugate

Trial Locations (8)

NEXT Virginia, Fairfax

Taipei Medical University - Shuang Ho Hospital, New Taipei City

Karmanos Cancer Institute, Detroit

The University of Texas MD Anderson Cancer Center, Houston

NEXT Oncology, San Antonio

California Clinical Trials Medical Group (CCTMG), Glendale

Scripps Green Hospital, La Jolla

Taipei Tzu Chi Hospital, New Taipei City